2015年3月5日讯 /生物谷BIOON/ --英国《金融时报(FT)》近日报道，强生（JNJ）即将与合作伙伴美国抗癌药商Pharmacyclics达成收购协议。如果属实，这将是全球最大医疗保健公司强生在一家生物制药公司押上的最大赌注，同时也将成为强生自2011年以213亿美元巨资收购瑞士医疗器械公司辛迪斯（Synthes）以来最大的一笔收购交易。
据知情人士透露，强生的报价将高出Pharmacyclics当前170亿美元市值，双方将在未来几天达成协议。不过该人士也表示，目前双方谈判尚未最终敲定，仍存在谈崩的可能性。消息发布后，Pharmacyclics公司股价应声上涨约7%。
强生总部位于美国新泽西州，Pharmacyclics位于美国加利福尼亚州，双方于2011年签署近10亿美元协议开始合作抗癌药物Imbruvica（ibrutinib），该药是一种首创的口服布鲁顿酪氨酸激酶（BTK）抑制剂，通过抑制肿瘤细胞复制和转移需要的布鲁顿酪氨酸激酶（BTK）而起到抗癌的作用。在美国及欧盟，Imbruvica均已获批用于套细胞淋巴细胞白血病（MCL）和慢性淋巴细胞白血病（CLL）的治疗，并于今年1月获FDA批准用于Waldenstrom巨球蛋白血症。业界此前预测，Imbruvica的年销售额峰值将突破50亿美元。
另一方面，开发治疗罕见病、孤儿药及难治性疾病的创新浪潮，也是推动制药巨头相互厮杀并购小型生物技术公司的重要因素。从今年开年，部分受强生收购的传言影响，Pharmacyclics公司股价已上涨83%。该公司在周三市值已达到170亿美元，强生市值为2820亿美元。
当前，医药领域的并购交易活动仍然非常活跃，而强生收购Pharmacyclics有望成为今年开年以来最新的大型并购交易。其他已完成的交易包括，Valeant耗资145亿美元收购胃肠道专科制药商Salix，辉瑞以170亿美元收购医疗设备制造商Hospira，而英国制药公司Shire以52亿美元收购NPS制药。
英文原文：J&J nearing deal to buy Pharmacyclics
Johnson & Johnson is nearing a deal to acquire US cancer drugmaker Pharmacyclics in what would be the biggest bet on a biopharmaceutical company by the world's largest maker of healthcare products.
According to people familiar with the matter, a bid from J&J is expected to value Pharmacyclics at a premium to its current $17bn market capitalisation and could be agreed in the coming days. These people warned that the talks have not been finalised and may still fall apart, report Arash Massoudi, Neil Hume, David Crow and James Fontanella-Khan.
Shares in Pharmacyclics were up about 7 per cent in US trading on Wednesday,
A deal would follow years of extensive collaboration between New Jersey-based J&J and California-based Pharmacyclics in developing a drug to treat blood cancer.
The duo won expanded approval from US health regulators in late January for a breakthrough drug called Imbruvica, which helps fight a rare form of cancer that begins in the body's immune system. The transaction would be the biggest for J&J since its struck a deal to acquire specialised surgical device maker Synthes for $21.3bn in 2011.
It also comes as a wave of innovation in developing treatments to rare, orphan or hard to treat diseases is leading to steep competition among large healthcare companies to acquire leading labs that have specific, specialised treatments.
Shares in Pharmacyclics are up 83 per cent from the start of the year, prompted in part by speculation that was weighing interest from suitors such as J&J. The company had a market capitalisation of $17bn on Wednesday, compared with $282bn for J&J.
A deal would be the latest large scale transaction this year in a sector where dealmaking remains extremely active. Since the start of the year, Valeant has acquired gastrointestinal drugmaker Salix for $14.5bn, Pfizer bought medical device maker Hospira for $17bn and the UK's Shire picked up NPS Pharma for $5.2bn.